(Q35563879)

English

Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation

scientific article published on November 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation (English)

1 reference

Europe PubMed Central

8 August 2017

transition metal

1 reference

based on heuristic

inferred from title

free radical scavengers

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568008

23 March 2024

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

author name string

Toshio Miyata

1

1 reference

Europe PubMed Central

8 August 2017

Charles van Ypersele de Strihou

2

1 reference

Europe PubMed Central

8 August 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

8 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0003986103004284?httpAccept=text/xml

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

https://api.elsevier.com/content/article/PII:S0003986103004284?httpAccept=text/plain

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Archives of Biochemistry and Biophysics

1 reference

Europe PubMed Central

8 August 2017

419

1 reference

Europe PubMed Central

8 August 2017

50-54

1 reference

Europe PubMed Central

8 August 2017

1

1 reference

Europe PubMed Central

8 August 2017

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits

2

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM

3

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus

4

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications

5

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

6

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation

7

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids

12

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60c-Src

13

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage

14

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

15

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis

16

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen

17

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction

18

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose

20

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Role of oxidative stress in development of complications in diabetes

22

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Chelating activity of advanced glycation end-product inhibitors

23

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Transition metals redox: reviving an old plot for diabetic vascular disease

24

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

25

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model

27

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine

29

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

30

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.

31

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

32

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

33

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

34

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

35

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

36

1 reference

10.1016/J.ABB.2003.08.010

https://api.crossref.org/works/10.1016/J.ABB.2003.08.010

23 March 2024

Identifiers

10.1016/J.ABB.2003.08.010

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35563879&oldid=2108898709"